Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cocrystal Pharma, Inc. on September 20, 2018. The report details executive compensation adjustments and equity grants approved by the Compensation Committee of the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and compensation matters.
Material Changes
- CEO Salary Increase: On September 20, 2018, the annual base salary for Dr. Gary Wilcox, Chief Executive Officer, was increased from $100,000 to $200,000, effective immediately.
- Equity Grants: On September 21, 2018, the Committee approved stock option grants under the 2015 Equity Incentive Plan with an exercise price of $2.78 per share (closing price on the Grant Date):
- 200,000 Incentive Stock Options to Dr. Gary Wilcox (CEO).
- 150,000 Incentive Stock Options to Mr. James Martin (CFO).
- 100,000 Incentive Stock Options to Dr. Sam Lee (President).
- 50,000 non-qualified stock options to each director, excluding Dr. Wilcox.
- Vesting Schedule: Options have a 10-year term. 25% vests on the one-year anniversary of the Grant Date; the remaining 75% vests in 12 equal quarterly increments, subject to continued service.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on operations, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the immediate 100% increase in the CEO's base salary.
- Confirm the total number of shares subject to the new option grants and their impact on dilution.
- Review the vesting conditions to understand the retention timeline for key executives.
- Check the current stock price relative to the $2.78 exercise price to assess the intrinsic value of the grants.